Brief: Enlivex Reports Dosing Of First Two Patients In Phase Ii Clinical Trial Evaluating Allocetra In Severe And Critical Covid-19 Patients
22/10/2020 13:47
Oct 22 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX REPORTS DOSING OF FIRST TWO PATIENTS IN PHASE II
CLINICAL TRIAL EVALUATING ALLOCETRA IN SEVERE AND CRITICAL
COVID-19 PATIENTS
* ENLIVEX THERAPEUTICS LTD - TRIAL IS EXPECTED TO RECRUIT UP
TO
TWENTY-FOUR COVID-19 PATIENTS IN SEVERE OR CRITICAL CONDITION
Source text for Eikon: ID:nGNX21GsZm
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment